{"public_id":"cl_c5bd1500da386f8bdbdc5d371d0a0d49","status":"active","superseded_by_public_id":null,"corpus_id":8302472,"text":"No molecular responses were observed when adherence was 80% or less.","confidence":0.95,"paper":{"corpus_id":8302472,"title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","url":"https://sah.borca.ai/papers/8302472"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_17cd7cde450541fe99676bfe3a32e529","name":"adherence","description":"The extent to which patients took imatinib as prescribed, measured with a microelectronic monitoring device.","types":["measure"],"url":"https://sah.borca.ai/concepts/co_17cd7cde450541fe99676bfe3a32e529"},{"public_id":"co_97acd5995d5308e3cad2847a0c1695dc","name":"molecular response","description":"The reduction or disappearance of BCR-ABL1 transcript levels used to evaluate treatment effect.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_97acd5995d5308e3cad2847a0c1695dc"},{"public_id":"co_eacaee09a4e3b378dd2ebd611e5e5f7c","name":"imatinib","description":"A tyrosine kinase inhibitor used as the treatment in the reported chronic myeloid leukemia cohort.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_eacaee09a4e3b378dd2ebd611e5e5f7c"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_c5bd1500da386f8bdbdc5d371d0a0d49"}